These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38031005)

  • 1. Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.
    Lashilola S; Xu W; Azimpour K; McCarthy M; Carlot S; Game D; van der Voort J
    BMC Nephrol; 2023 Nov; 24(1):351. PubMed ID: 38031005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
    Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
    Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
    Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
    van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
    Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
    Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E
    Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.
    Nießl C; Boulesteix AL; Oh J; Palm K; Schlingmann P; Wygoda S; Haffner D; Wühl E; Tönshoff B; Buescher A; Billing H; Hoppe B; Zirngibl M; Kettwig M; Moeller K; Acham-Roschitz B; Arbeiter K; Bald M; Benz M; Galiano M; John-Kroegel U; Klaus G; Marx-Berger D; Moser K; Mueller D; Patzer L; Pohl M; Seitz B; Treikauskas U; von Vigier RO; Gahl WA; Hohenfellner K
    Mol Genet Metab; 2022 Aug; 136(4):268-273. PubMed ID: 35835062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
    Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
    Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
    Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
    Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
    Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
    da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
    N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").
    Langman CB
    Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
    Gahl WA; Balog JZ; Kleta R
    Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worldwide disparities in access to treatment and investigations for nephropathic cystinosis: a 2023 perspective.
    Regnier M; Flammier S; Boutaba M; Ndongo AA; Servais A; Schaefer F; Levtchenko E; Bacchetta J; Bertholet-Thomas A
    Pediatr Nephrol; 2024 Apr; 39(4):1113-1123. PubMed ID: 37978055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
    Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
    J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.